Page last updated: 2024-08-21

arsenic trioxide and Lupus Erythematosus, Systemic

arsenic trioxide has been researched along with Lupus Erythematosus, Systemic in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Amoura, Z; Ebbo, M; Gaborit, B; Hachulla, E; Hamidou, M; Hardouin, JB; Néel, A; Poupon, J; Rieger, F; Sibilia, J; Viallard, JF; Volteau, C1
Chen, E; Hu, H; Li, Y; Zhang, T; Zhu, X1
Bobé, P; Chelbi-Alix, MK1
Benihoud, K; Bobé, P; Bonardelle, D; Chelbi-Alix, MK; Opolon, P1
Lin, SX; Xia, XR; Zhou, Y1

Trials

1 trial(s) available for arsenic trioxide and Lupus Erythematosus, Systemic

ArticleYear
Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic).
    Arthritis research & therapy, 2021, 03-03, Volume: 23, Issue:1

    Topics: Adult; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Severity of Illness Index; Treatment Outcome

2021

Other Studies

4 other study(ies) available for arsenic trioxide and Lupus Erythematosus, Systemic

ArticleYear
Effects of Arsenic Trioxide on INF-gamma Gene Expression in MRL/lpr Mice and Human Lupus.
    Biological trace element research, 2018, Volume: 184, Issue:2

    Topics: Adult; Animals; Arsenic Trioxide; Arsenicals; Cells, Cultured; Female; Gene Expression; Humans; Interferon-gamma; Leukocytes, Mononuclear; Lupus Erythematosus, Systemic; Male; Mice, Inbred C57BL; Mice, Inbred MRL lpr; Oxides; Spleen; Young Adult

2018
[New therapeutic perspectives for arsenic: from acute promyelocytic leukemia to autoimmune diseases].
    Medecine sciences : M/S, 2008, Volume: 24, Issue:11

    Topics: Animals; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Autoimmune Diseases; Disease Models, Animal; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Mice; Oxides

2008
Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice.
    Blood, 2006, Dec-15, Volume: 108, Issue:13

    Topics: Animals; Antibodies, Antinuclear; Antigen-Antibody Complex; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cytokines; Drug Evaluation, Preclinical; Enzyme Activation; fas Receptor; Glutathione; Humans; Lupus Erythematosus, Systemic; Lymphocyte Activation; Lymphoproliferative Disorders; Mice; Mice, Inbred MRL lpr; Nitric Oxide; Oxidation-Reduction; Oxides; Syndrome

2006
[Effects of arsenic trioxide on the autoimmunity and survival time in BXSB lupus mice].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2007, Volume: 27, Issue:2

    Topics: Animals; Antibodies, Antinuclear; Arsenic Trioxide; Arsenicals; Autoimmunity; Enzyme-Linked Immunosorbent Assay; Immunoglobulin G; Injections, Intraperitoneal; Interferon-gamma; Kidney; Lupus Erythematosus, Systemic; Mice; Oxides; Random Allocation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spleen; Survival Analysis

2007